Prourocare Medical Inc. - Statement of Changes in Beneficial Ownership (4)
July 15 2008 - 5:45PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Expires:
February 28, 2011
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Rudelius Robert James
|
2. Issuer Name
and
Ticker or Trading Symbol
ProUroCare Medical Inc.
[
PUMD
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__
X
__ Director
_____ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
(Last)
(First)
(Middle)
6913 ARBOR LANE
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
7/11/2008
|
(Street)
MCCLEAN, VA 22101
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock, $0.00001 par value
|
7/11/2008
|
|
P
(11)
|
|
4792
|
A
|
$1.00
|
5209
|
D
|
|
Common Stock, $0.00001 par value
|
7/11/2008
|
|
J
(12)
|
|
10000
|
A
|
$1.00
|
15209
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Options
|
$2.90
|
|
|
|
|
|
|
(1)
|
6/12/2014
|
Common Stock, $0.00001 par value
|
3000
|
|
3000
|
D
|
|
Warrants
|
(2)
|
|
|
|
|
|
|
(3)
|
12/31/2012
|
Common Stock, $0.00001 par value
|
4000
|
|
4000
|
D
|
|
Convertible Promissory Notes
|
(4)
|
|
|
|
|
|
|
(6)
|
6/27/2009
|
Common stock, $0.00001 par value
|
(5)
(7)
|
|
$19000
|
D
|
|
Convertible Promissory Notes
|
(8)
|
|
|
|
|
|
|
(6)
|
8/13/2009
|
Common stock, $0.00001 par value
|
(7)
(9)
|
|
$9500
|
I
|
By Noble Ventures, of which reporting person is the majority owner
|
Warrants
|
(2)
|
|
|
|
|
|
|
(10)
|
12/31/2012
|
Common stock, $.00001 par value
|
2000
|
|
2000
|
I
|
By Noble Ventures, of which reporting person is the majority owner
|
Explanation of Responses:
|
(
1)
|
1,000 options vested as of February 28, 2008; remaining options vest as to 125 shares per month.
|
(
2)
|
Each warrant is exercisable into common stock at 50% of the per share price of equity securities issued in a public offering. in the event that ProUroCare Medical Inc. fails to close a public offering prior to June 27, 2009, each warrant will be exercisable at 50% of the closing price of ProUroCare Medical Inc.'s common stock on that date.
|
(
3)
|
Each of the warrants will become exercisable upon the earlier of the closing of an underwritten public offering or June 27, 2009.
|
(
4)
|
The Notes and any accrued interest thereon are convertible into common stock at 70% of the per share price of equity securities issued in a public offering. In the event that ProUroCare Medical Inc. fails to close a public offering prior to June 27, 2009, the Notes and any accrued interest thereon will be convertible into common stock at $0.05 per share.
|
(
5)
|
The number of shares that the notes are convertible into depends upon the converion price that is to be determined at the time of an underwritten public offering. If ProUroCare Medical Inc. fails to close on an underwritten public offering by June 27, 2009 and fails to prepay the notes, the notes will be convertible into 380,000 shares of common stock.
|
(
6)
|
The notes are convertible into common stock upon the closing of an underwritten public offering of equity securities by ProUroCare Medical Inc.
|
(
7)
|
Principal amount. Interest accrues at 10%, and is convertible into common stock as well.
|
(
8)
|
The Notes and any accrued interest thereon are convertible into common stock at 70% of the per share price of equity securities issued in a public offering. In the event that ProUroCare Medical Inc. fails to close a public offering prior to August 13, 2009, the Notes and any accrued interest thereon will be convertible into common stock at $0.05 per share.
|
(
9)
|
The number of shares that the notes are convertible into depends upon the converion price that is to be determined at the time of an underwritten public offering. If ProUroCare Medical Inc. fails to close on an underwritten public offering by August 13, 2009 and fails to prepay the notes, the notes will be convertible into 190,000 shares of common stock.
|
(
10)
|
Each of the warrants will become exercisable upon the earlier of the closing of an underwritten public offering or August 13, 2009.
|
(
11)
|
Issued to reporting person in lieu of cash for accrued director's fees.
|
(
12)
|
Issued to reporting person in recognition of extraordinary time and effort spent of the Company's restructuring and refinancing since January 2007.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Rudelius Robert James
6913 ARBOR LANE
MCCLEAN, VA 22101
|
X
|
|
|
|
Signatures
|
Richard B. Thon by power of attorney
|
|
7/14/2008
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
ProUroCare Medical (CE) (USOTC:PUMD)
Historical Stock Chart
From Jun 2024 to Jul 2024
ProUroCare Medical (CE) (USOTC:PUMD)
Historical Stock Chart
From Jul 2023 to Jul 2024